【Everlight Bio-Tech】Announcement of the company's board of directors' approval of the Q1 2026 individual financial report
NQ Score
0/100
N1 Content Completeness
5
AI Summary (NQ-processed)
Everlight Bio-Tech announced that its individual financial report for the first quarter of 2026 (January 1 to March 31) was approved by the board of directors on April 29, 2026. During this period, operating revenue was NT$368.422 million, pre-tax net profit was NT$53.254 million, and net profit attributable to owners of the parent company was NT$43.737 million.